Anti-PD-1 immunotherapyImmune checkpoint inhibitorsNivolumabPembrolizumabImmunotherapy with immune checkpoint inhibitors, such as anti-PD-1 drugs, is an area in increasing development for its efficacy and advantages in the treatment of advanced metastatic melanoma. In fact, immunotherapy has been the ...
Sintilimab (IBI308), an IgG4 monoclonal antibody, blocks PD-1, enhancing T-cell anti-tumor response; treats Hodgkin's, lung, and esophageal cancers.
Anti-PD-1 monoclonal antibody, produced by Suzhou Pharmaceutical Enterprise and first developed by China, was put into operation on Dec. 17, 2018 after it was approved for sale under the trade name "Tuo Yi". The price of the drug was officially announced on January 8, 7200 yuan (240 mg)...
Programmed death 1 expression in cancer and infection: tissue versus periphery PD-1:PD-L1 blockade as host-directed therapy Anti-PD-1:PD-L1/2 therapy: improved efficacy with acceptable toxicity Anti-PD-1 versus anti-PD-L1/2 therapy and opportunities for combination with other immunotherapies Conc...
Furthermore, our in vivo studies revealed that inhibiting S100A9 can synergistically enhance the efficacy of anti-PD-1 drugs in the eradication of hepatocellular carcinoma. Conclusions Our study underscores the significance of S100A9+CD14+ monocytes in predicting inadequate response to ICB treatment and...
(pucotenlimab injection) is a humanized IgG4 monoclonal antibody against human PD-1 independently developed in China. It can bind to PD-1 with high affinity to restore the ability of immune cells to kill cancer cells by blocking the binding of PD-1 to its ligands PD-L1 and PD-L2. Pu...
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy PURPOSE: Immunomodulatory drugs differ in mechanism-of-action from directly cytotoxic cancer therapies. Identifying factors predicting clinical response co... JM Taube,A Kle...
FDA: Food and Drug Administration; Ig: immunoglobulin; mAb: monoclonal antibody; NSCLC: non-small-cell lung cancer; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; PD-L2: programmed death-ligand 2. Table 2.PD-L1 IHC assay systems as companion and complementary diagnostic assays...
Immunotherapy targeting PD-1 is one of the most prevalent approaches, but it has a low response rate in most patients, particularly those with microsatellite stability (MSS). Recently, some targeted drugs have been found to remarkably enhance the anti-tumor immunity of cancer models, mainly ...
forward the first anti-PD-1 therapy for advanced melanoma in China.” “The approval of our anti-PD-1 therapy reflects the Chinese government’s strong commitment to expedite the introduction of innovative therapies to Chinese patients,” said Joseph Romanelli, president of MSD ...